(19)
(11) EP 1 373 502 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.12.2010 Bulletin 2010/51

(45) Mention of the grant of the patent:
20.10.2010 Bulletin 2010/42

(21) Application number: 02706572.1

(22) Date of filing: 20.03.2002
(51) International Patent Classification (IPC): 
C12N 15/12(2006.01)
A61K 38/17(2006.01)
C12N 15/861(2006.01)
 C07K 14/47(2006.01)
C12N 5/07(2010.01)
C12N 15/867(2006.01)
(86) International application number:
PCT/CA2002/000373
(87) International publication number:
WO 2002/074956 (26.09.2002 Gazette 2002/39)

(54)

DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF

Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen

FACTEURS PROMOTEURS DE LA SURVIE DES NEURONES DOPAMINERGIQUES ET UTILISATIONS ASSOCIEES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 20.03.2001 US 277516 P

(43) Date of publication of application:
02.01.2004 Bulletin 2004/01

(73) Proprietor: Amarantus Therapeutics, Inc.
Palo Alto, CA 94301-1704 (US)

(72) Inventors:
  • COMMISSIONG, John, W.
    Mississauga, Ontario L5B 3T7 (CA)
  • RAIBEKAS, Andrei, A.
    Newbury Park, CA 91320 (US)

(74) Representative: Wilkinson, Marc George et al
HLBBshaw Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ
Epping, Essex CM16 5DQ (GB)


(56) References cited: : 
WO-A-01/19851
WO-A-01/70174
WO-A-02/98902
WO-A-02/079246
WO-A-02/090541
 WO-A-01/25427
WO-A-01/70174
WO-A-02/98902
WO-A-02/079246
WO-A-02/090541
   
  • PANCHISION D M ET AL: "AN IMMORTALIZED, TYPE-1 ASTROCYTE OF MESENCEPHALIC ORIGIN SOURCE OF A DOPAMINERGIC NEUROTROPHIC FACTOR" JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 11, no. 3, December 1998 (1998-12), pages 209-221, XP000943928 ISSN: 0895-8696
  • SHRIDHAR V ET AL: "A GENE FROM HUMAN CHROMOSOMAL BAND 3P21.1 ENCODES A HIGHLY CONSERVED ARGININE-RICH PROTEIN AND IS MUTATED IN RENAL CELL CARCINOMAS" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 9, 2 May 1996 (1996-05-02), pages 1931-1938, XP002906046 ISSN: 0950-9232
  • MAYER E ET AL: "Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons: I. Effects in vitro." NEUROSCIENCE, vol. 56, no. 2, 1993, pages 379-388, XP002239165 ISSN: 0306-4522
  • MAYER E ET AL: "Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons: II. Effects on nigral transplants in vivo." NEUROSCIENCE, vol. 56, no. 2, 1993, pages 389-398, XP008016493 ISSN: 0306-4522
  • DATABASE JPOP [Online] 27 August 2002 (2002-08-27) NOJIMA H. ET AL.: "Shear stress-responsive DNAs" retrieved from EBI Database accession no. BD539164 XP002239166
  • PETROVA P.S. ET AL.: J.MOL.NEUROSCI., vol. 20, 2003, pages 173-187,
  • DATABASE UniProt [Online] 10 February 2009 (2009-02-10), retrieved from EBI Database accession no. ARMET_HUMAN
  • PETROVA P.S. ET AL.: J.MOL.NEUROSCI., vol. 20, 2003, pages 173-187,
  • DATABASE UniProt [Online] 10 February 2009 (2009-02-10), retrieved from EBI Database accession no. ARMET_HUMAN
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).